Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.
AuthorsDean, Emma J
Middleton, M R
Ranson, Malcolm R
AffiliationClinical Trials Unit, Department of Medical Oncology, The Christie NHS Foundation Trust, The University of Manchester, Wilmslow Road, Manchester M20 4, BX, UK. email@example.com
MetadataShow full item record
AbstractOlaparib (AZD2281) is a potent oral poly(ADP-ribose) polymerase inhibitor with anti-tumour activity and acceptable toxicity as monotherapy in patients with BRCA-deficient cancers. The vascular endothelial growth factor receptor inhibitor bevacizumab has been incorporated into standard of care with chemotherapy in various tumours. This phase I study established the safety, tolerability and clinical pharmacokinetics of olaparib alone and in combination with bevacizumab.
CitationPhase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. 2012, 106 (3):468-74 Br J Cancer
JournalBritish Journal of Cancer